Literature DB >> 23792121

A multicenter study of neurocognition in children with hypertension: methods, challenges, and solutions.

Marc B Lande1, Heather R Adams, Juan C Kupferman, Stephen R Hooper, Peter G Szilagyi, Donald L Batisky.   

Abstract

Hypertensive adults demonstrate decreased performance on neurocognitive testing compared with that of normotensive controls. There is now emerging, preliminary evidence that children with hypertension also manifest neurocognitive differences when compared with normotensive controls, findings postulated to potentially represent early signs of hypertensive target organ damage to the brain. However, reports in children to date have been limited to database and single-center studies. We have established an ongoing, prospective, multicenter study of neurocognition in children with primary hypertension. This article outlines the study methods, with particular attention to the unique challenges in this area of clinical research. We highlight aspects of the study design that are specifically designed as solutions to these challenges.
Copyright © 2013 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Executive function; blood pressure; cognition; pediatric

Mesh:

Year:  2013        PMID: 23792121      PMCID: PMC3783545          DOI: 10.1016/j.jash.2013.05.003

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  24 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals.

Authors:  Marina G Falleti; Paul Maruff; Alexander Collie; David G Darby
Journal:  J Clin Exp Neuropsychol       Date:  2006-10       Impact factor: 2.475

Review 3.  Executive functions and developmental psychopathology.

Authors:  B F Pennington; S Ozonoff
Journal:  J Child Psychol Psychiatry       Date:  1996-01       Impact factor: 8.982

4.  Sleep schedules and daytime functioning in adolescents.

Authors:  A R Wolfson; M A Carskadon
Journal:  Child Dev       Date:  1998-08

5.  Negative affect as a prospective risk factor for hypertension.

Authors:  B S Jonas; J F Lando
Journal:  Psychosom Med       Date:  2000 Mar-Apr       Impact factor: 4.312

Review 6.  Neurocognitive consequences of sleep deprivation.

Authors:  Jeffrey S Durmer; David F Dinges
Journal:  Semin Neurol       Date:  2005-03       Impact factor: 3.420

Review 7.  Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review.

Authors:  Erik G Willcutt; Alysa E Doyle; Joel T Nigg; Stephen V Faraone; Bruce F Pennington
Journal:  Biol Psychiatry       Date:  2005-06-01       Impact factor: 13.382

8.  How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists.

Authors:  Robert P Woroniecki; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2005-04-05       Impact factor: 3.714

Review 9.  Ethics of placebo use in pediatric clinical trials: the case of antihypertensive drug studies.

Authors:  Joseph T Flynn
Journal:  Hypertension       Date:  2003-09-22       Impact factor: 10.190

10.  Obesity and metabolic syndrome and functional and structural brain impairments in adolescence.

Authors:  Po Lai Yau; Mary Grace Castro; Adrian Tagani; Wai Hon Tsui; Antonio Convit
Journal:  Pediatrics       Date:  2012-09-03       Impact factor: 7.124

View more
  9 in total

1.  Ambulatory blood pressure monitoring and neurocognitive function in children with primary hypertension.

Authors:  Juan C Kupferman; Donald L Batisky; Joshua Samuels; Heather R Adams; Stephen R Hooper; Hongyue Wang; Marc B Lande
Journal:  Pediatr Nephrol       Date:  2018-06-12       Impact factor: 3.714

Review 2.  Cognitive function in hypertensive children.

Authors:  Marc B Lande; Juan C Kupferman
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

Review 3.  Neurocognition in Pediatric Chronic Kidney Disease: A Review of Data From the Chronic Kidney Disease in Children (CKiD) Study.

Authors:  Rebecca J Johnson; Lyndsay A Harshman
Journal:  Semin Nephrol       Date:  2021-09       Impact factor: 4.472

4.  Screening blood pressure measurement in children: are we saving lives?

Authors:  Tammy M Brady; Karen M Redwine; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

5.  Neurocognitive Function in Children with Primary Hypertension after Initiation of Antihypertensive Therapy.

Authors:  Marc B Lande; Donald L Batisky; Juan C Kupferman; Joshua Samuels; Stephen R Hooper; Bonita Falkner; Shari R Waldstein; Peter G Szilagyi; Hongyue Wang; Jennifer Staskiewicz; Heather R Adams
Journal:  J Pediatr       Date:  2018-02-03       Impact factor: 4.406

6.  Neurocognitive Function in Children with Primary Hypertension.

Authors:  Marc B Lande; Donald L Batisky; Juan C Kupferman; Joshua Samuels; Stephen R Hooper; Bonita Falkner; Shari R Waldstein; Peter G Szilagyi; Hongyue Wang; Jennifer Staskiewicz; Heather R Adams
Journal:  J Pediatr       Date:  2016-09-29       Impact factor: 4.406

Review 7.  Blood Pressure and Cognitive Function in Children and Adolescents.

Authors:  Marc B Lande; Juan C Kupferman
Journal:  Hypertension       Date:  2019-03       Impact factor: 10.190

8.  Sleep disordered breathing as measured by SRBD-PSQ and neurocognition in children with hypertension.

Authors:  Marc B Lande; Stephen R Hooper; Donald L Batisky; Juan C Kupferman; Peter G Szilagyi; Joshua A Samuels; Heather R Adams
Journal:  Am J Hypertens       Date:  2014-09-20       Impact factor: 2.689

9.  Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews.

Authors:  April V P Clyburne-Sherin; Pravheen Thurairajah; Mufiza Z Kapadia; Margaret Sampson; Winnie W Y Chan; Martin Offringa
Journal:  Trials       Date:  2015-09-18       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.